ConclusionOur findings suggest that MSN and ARFIP2 could serve as promising biomarkers for predicting response to Tz, offering valuable insights for future research in the identification of diagnostic and therapeutic targets for BC patients with Tz resistance. (Source: Breast Cancer Research and Treatment)

ConclusionPD-L1 (SP142) status changes after NAC, mostly as a positive conversion. As PD-L1 (SP142) status can convey prognostic and predictive information, it needs to be tested before and after NAC. (Source: Breast Cancer Research and Treatment)

ConclusionBlack patients expressed more interest in IM than their White counterparts; there were no racial differences in IM use, except lower acupuncture use among Black patients. A breast program focused on equity should provide access to these services for patients with breast cancer. (Source: Breast Cancer Research and Treatment)

ConclusionAR localization is an acceptable alternative to ultrasound-guided skin marking with no significant differences in surgical outcomes. (Source: Breast Cancer Research and Treatment)

ConclusionsEvaluation of cfDNAI 2 weeks after NAC initiation appears to be an early biomarker for tumor pCR and DFS. Measuring Alu fragments of different lengths may replace techniques requiring prior tumor sequencing to measure ctDNA, reducing costs and complexity of cfDNA serial measurements in BC patients undergoing NAC. (Source: Breast Cancer Research...

ConclusionThe application of plasma metabolomics, utilizing CE-MS and LC –MS, may serve as a tool for predicting the efficacy of neoadjuvant chemotherapy in breast cancer in the future after all necessary validations have been completed. (Source: Breast Cancer Research and Treatment)